The two papers in this issue that address the management of primary gastric lymphoma have more in common than does the disease under discussion. Both consider questions surrounding the management of a relatively common presentation that accounts for approximately 20%-30% of all patients with localised extranodal lymphoma [1] . However, it is still a relatively rare presentation that accounts for no more than 5% of all new lymphoma cases [1, 2] . The authors analyse the outcomes and prognostic factors in heterogeneous groups of patients collected over 16-25 years and managed with a variety of treatment methods. Both papers propose some modifications to the current staging or prognostic systems.
Cortelazzo et al. report the outcomes in 312 patients with stage I and II diffuse large-cell B-cell lymphoma of the stomach, treated in Switzerland and Italy with a variety of approaches over 25 years, and propose a new 'stage-modified' International Prognostic Index. Ibrahim et al. report the outcomes in 185 patients with stage I-IV primary gastric lymphoma treated in Saudi Arabia with a variety of approaches between 1982 and 1998, and propose their own version of 'prognostic index' while at the same time embracing the 'Lugano staging classification' for gastrointestinal lymphoma.
Both authors correctly identify that the extent of lymph node involvement affects the outcome in gastric lymphoma. There is also evidence that the extent of nodal involvement is of prognostic significance in both Hodgkin's disease and non-Hodgkin's lymphomas. In fact, Vera Peters proposed the separation of the 'localised stage II' from the 'extensive stage II' lymphomas [3] [4] [5] . The Ann Arbor staging classification was agreed upon at a meeting of experts and interested parties that took place in Ann Arbor Michigan in 1971 and has been put to use for almost 30 years [6] . The arbitrary distinction between stage II and stage III based on the location of nodal involvement in relation to the diaphragm was a pragmatic decision driven by issues related to the application of radiation therapy, then the most prevalent form of treatment.
The Ann Arbor classification although not perfect, has allowed the clinicians dealing with lymphomas to communicate in an unambiguous manner for many years. Indeed, the use of staging classification in lymphomas preceded the use of uniform, internationally recognised staging classifications in other malignancies.
Unlike the personal staging systems popularised for solid tumours such as colon, kidney, bladder, etc., no modifications to the Ann Arbor classification have been accepted. Lymphoma experts have not experienced the difficulties of interpreting multiple personal revisions of staging classifications like Duke, Duke-Astler, and modified Duke's in colon cancer, or Jewett-Strong, Whitmore etc. in urologic cancers. The International Union against Cancer (UICC) has attempted to standardise and unify staging classifications since the 1950s. Since most hematologic malignancies do not lend themselves easily to theTNM system, the UICC has accepted the Ann Arbor classification as its standard staging system for lymphomas and Hodgkin's disease. In 1987, unification of the UICC and the AJCC staging classifications has permitted the uniform approach to cancer staging world-wide [7, 8] .
The Ann Arbor classification, similar to the TNM classifications, addresses mainly the issues of anatomic disease extent. The TNM founder, Pierre Denoix recognised, as early as 1950, that other prognostic factors that may affect the outcome are not represented in the TNM system [9] . In the past decades, thousands of publications addressed issues of prognostic factors in cancer. As a result of these studies, the prognostic factors are known to be tumour related, host or patient related, or treatment, or in a broader sense, environment related [10] . A large number of prognostic factors have been recognised as essential in predicting the outcome. They included among others, stage, presence of systemic symptoms, tumour bulk, LDH, extent of extranodal involvement, histologic type, patient's age, and treatment [11] [12] [13] [14] . In 1993, a group of investigators studied prognostic factors in malignant lymphomas in a large number of patients with diffuse large-cell lymphoma treated with doxorubicin-based chemotherapy and developed a prognostic index, referred to as IPI (International Prognostic Index for malignant lymphomas) [15] . Since then, the IPI has been validated in a number of large groups of patients with lymphomas [16] [17] [18] [19] [20] [21] [22] . The IPI was based on factors previously known to affect the outcome in lymphomas that were available for analysis in large patient populations. Unlike studies of new therapeutic approaches that are prospective and often randomised, studies of prognostic factors are mostly 'add on' projects in retrospective analysis of treatment outcomes [23] . No a priori hypotheses are formulated, and the potential type II errors are frequently neglected. The modifications to the IPI proposed by Ibrahim may be considered harmless by some, but they undermine the uniform application of the IPI without a visible lasting benefit.
The purpose of staging and prognostic groupings is to help to communicate prognosis, to facilitate comparison of treatment results, and to identify factors that predict for treatment success or failure. This is done in anticipation of applying an alternative treatment approach to those patients who fail traditional therapy. No such efforts are evident in the publications under consideration. The prognostic factors are often specific for a given treatment strategy. For example, tumour bulk is often important in chemotherapy or radiation treated patients, while the presence of unresectable disease, or residual tumour may be more important in patients treated with surgery. Therefore the attempts to analyse prognostic factors without considering the treatment context may be misleading.
The outcomes in stage I and II gastric lymphoma are consistently better than for nodal lymphomas of the same stage [1, 24] . This may now be recognised as related to the low probability of occult distant disease in MALTextranodal lymphomas. The achievement of local control in gastric lymphoma is therefore translated into high cure rates. Unfortunately, neither of the two papers described above embarked on a detailed analysis of the site of treatment failure in relation to treatment received.
Do we know how to best treat the patients with localised gastric lymphoma in 1999? There are no reasons to believe that the approach to the management of diffuse large-cell gastric lymphoma should be different to that for diffuse large-cell nodal lymphoma. Prospective randomised trials conducted 20 years ago documented an improved outcome for diffuse large cell lymphomas treated with chemotherapy followed by radiation therapy compared to the traditional treatment with radiation therapy alone [25] . The improvement was due to better local control and decreased distant relapse rate. The two large prospective randomised trials conducted by SWOG and ECOG established that chemotherapy followed by involved field radiation therapy offers better disease control and survival than treatment with chemotherapy alone [26, 27] . The issue of a surgery-based approach to the management of primary gastric lymphoma versus chemotherapy-based approach has never been a subject of a randomized trial. However, with mature data showing efficacy of a conservative approach, gastrectomy has virtually been abandoned in the management of gastric lymphomas [28] [29] [30] [31] .
These two papers describing the outcomes in primary gastric lymphoma draw our attention to the excellent survival expected in this disease. They also raise questions as to whether minor improvements in prognostic ability justify an individualistic approach to classification. The alternative view, for which there is much support in cancer control and quality improvement fields, is that a uniform approach to staging and prognostic classifications for all lymphomas should be embraced. Reduced variation in reporting is essential to improved communication and audit of medical practice.
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